Publications
Diabetes, Obesity and Metabolism. Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal? [Internet]. 2024;Available from: https://doi.org/10.1111/dom.15459
. Diabetes, Obesity and Metabolism. Insulin, hypoglycaemia and dementia: A causal mediation analysis showcasing challenges and potential opportunities [Internet]. 2024;Available from: https://doi.org/10.1111/dom.15385
. British Journal of Clinical Pharmacology. Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors [Internet]. 2023;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85124712639&partnerID=MN8TOARS
. Canadian Journal of Diabetes. Prescribing Trends of the Sodium–Glucose Cotransporter-2 Inhibitors Among Different Physician Specialties in Canada (2015–2021) [Internet]. 2023;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85143981743&partnerID=MN8TOARS
. Diabetes Care. Associations of Mid-and Late-Life Severe Hypoglycemic Episodes With Incident Dementia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study [Internet]. 2023;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85147047452&partnerID=MN8TOARS
. Diabetes Care. Insulin Use in Type 2 Diabetes and the Risk of Dementia: A Comparative Population-Based Cohort Study [Internet]. 2023;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85165521395&partnerID=MN8TOARS
. Diabetes, Obesity and Metabolism. Post-initiation predictors of discontinuation of the sodium-glucose cotransporter-2 inhibitors: A comparative cohort study from the United Kingdom [Internet]. 2023;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85167588605&partnerID=MN8TOARS
. Drug Safety. Author’s Reply to Kuss and Rathmann’s Comment on: “Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data” [Internet]. 2023;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85152556353&partnerID=MN8TOARS
. International Journal of Epidemiology. Hypoglycaemia and the risk of dementia: a population-based cohort study using exposure density sampling [Internet]. 2023;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85147424628&partnerID=MN8TOARS
. Journal of Pharmaceutical Health Services Research. Trends in estimated total retail dispensed prescriptions of purported COVID-19 treatments and preventions in Canada [Internet]. 2023;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85163707017&partnerID=MN8TOARS
. American Journal of Medicine Open. Peak performance: Putting type 1 diabetes management recommendations for athletes to the test [Internet]. 2022;Available from: https://doi.org/10.1016/j.ajmo.2022.100011
. Canadian Journal of Diabetes. Trends and Determinants of Self-reported Aspirin Use Among Patients With Diabetes Stratified by Presence and Risk of Cardiovascular Diseases: A Repeated Pan-Canadian Cross-sectional Study [Internet]. 2022;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85129977549&partnerID=MN8TOARS
. Canadian Journal of Diabetes. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score–matched Population-based Cohort Study [Internet]. 2022;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85129507933&partnerID=MN8TOARS
Diabetes and Metabolism. Risk of hospitalization and death associated with sodium glucose cotransporter-2 inhibitors: A comparison with five other classes of antidiabetic drugs [Internet]. 2022;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85120915534&partnerID=MN8TOARS
Diabetic Medicine. Five comparative cohorts to assess the risk of genital tract infections associated with sodium-glucose cotransporter-2 inhibitors initiation in type 2 diabetes mellitus [Internet]. 2022;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85129462097&partnerID=MN8TOARS
Drug Safety. Drug–Drug Interaction of the Sodium Glucose Co-Transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data [Internet]. 2022;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85125655701&partnerID=MN8TOARS
. Drug Safety. Authors’ Reply to Noguchi’s comment on: “Drug-Drug Interaction of the Sodium Glucose Co-transporter 2 Inhibitors with Statins and Myopathy: A Disproportionality Analysis Using Adverse Events Reporting Data.” [Internet]. 2022;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85132201172&partnerID=MN8TOARS
. International Journal of COPD. Association between Inhaled β2-agonists Initiation and Risk of Major Adverse Cardiovascular Events: A Population-based Nested Case-Control Study [Internet]. 2022;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85131104214&partnerID=MN8TOARS
. Respiratory Research. Risk of all-cause mortality or hospitalization for pneumonia associated with inhaled β2-agonists in patients with asthma, COPD or asthma-COPD overlap [Internet]. 2022;Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85144299296&partnerID=MN8TOARS
. Association between Inhaled beta(2)-agonists Initiation and Risk of Major Adverse Cardiovascular Events: A Population-based Nested Case-Control Study. INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. 2022;17:1205-1217.
.